Ultrasound industry analystslooking for signs of a turnaround in the modality may have togo back to reading tea leaves, at least for the time being. Twoclosely watched modality leaders, Acuson and ATL, released a mixedbag of second-quarter financial
Ultrasound industry analystslooking for signs of a turnaround in the modality may have togo back to reading tea leaves, at least for the time being. Twoclosely watched modality leaders, Acuson and ATL, released a mixedbag of second-quarter financial results last month, with Acusonshowing improving fortunes while ATL's numbers remain mired.
Acuson of Mountain View, CA, posted the second consecutivequarter of surprisingly strong revenue and earnings growth. Acuson'ssales increased 22% in the quarter, to $88 million from $72.1million in the same period last year. Net income also jumped,to $4.1 million this year compared to a net loss of $6.7 millionin the second quarter of 1993. Last year's loss included a $12million charge for restructuring (SCAN 6/16/93).
Bothell, WA-based ATL, meanwhile, suffered from lower salesas well as the costs of its merger with Interspec earlier thisyear. ATL's second-quarter revenues were $84.8 million, down about5% compared to $89.2 million recorded a year ago (current andhistorical results include those of Interspec).
ATL reported a net loss for the quarter of $9.9 million, comparedto a loss of $1.6 million in the same period last year. This year'snumbers include a charge against earnings of $5.4 million forcosts associated with the Interspec merger.
While the numbers look good for Acuson, the company is stillcautious about whether the market is returning to the prosperousdays of yore.
"It is very hard to assess what the status of the marketis," said Acuson COO Robert Gallagher. "We continueto be very optimistic in the long term for ultrasound, but topick the exact turning point is hard."
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.
Study: Black Patients Less Likely Than Others to Receive MRI Assessment of Cognitive Impairment
November 27th 2023In a four-year study of over 1,600 patients who had outpatient head CTs, head CT angiography and/or brain MRI to assess cognitive impairment, researchers found that Black patients were over 9 percent less likely than White patients and over 16 percent less likely than Hispanic patients to receive brain MRI.